# A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

> **NCT01618695** · PHASE3 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 940 (actual)

## Conditions studied

- Partial-onset Seizures

## Interventions

- **DRUG:** Perampanel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01618695
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-15
- **Primary completion:** 2014-09-15
- **Final completion:** 2020-05-28
- **Target enrollment:** 940 (ACTUAL)
- **Last updated:** 2021-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01618695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01618695, "A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01618695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*